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Abstract
The monogenetic disease Spinal Muscular Atrophy (SMA) is characterized by a progressive loss of motoneurons leading to
muscle weakness and atrophy due to severe reduction of the Survival of Motoneuron (SMN) protein. Several models of SMA
show deficits in neurite outgrowth and maintenance of neuromuscular junction (NMJ) structure. Survival of motoneurons,
axonal outgrowth and formation of NMJ is controlled by neurotrophic factors such as the Fibroblast Growth Factor (FGF)
system. Besides their classical role as extracellular ligands, some FGFs exert also intracellular functions controlling neuronal
differentiation. We have previously shown that intracellular FGF-2 binds to SMN and regulates the number of a subtype of
nuclear bodies which are reduced in SMA patients. In the light of these findings, we systematically analyzed the FGF-system
comprising five canonical receptors and 22 ligands in a severe mouse model of SMA. In this study, we demonstrate
widespread alterations of the FGF-system in both muscle and spinal cord. Importantly, FGF-receptor 1 is upregulated in
spinal cord at a pre-symptomatic stage as well as in a mouse motoneuron-like cell-line NSC34 based model of SMA.
Consistent with that, phosphorylations of FGFR-downstream targets Akt and ERK are increased. Moreover, ERK hyper-
phosphorylation is functionally linked to FGFR-1 as revealed by receptor inhibition experiments. Our study shows that the
FGF system is dysregulated at an early stage in SMA and may contribute to the SMA pathogenesis.
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Introduction
Juvenile Spinal Muscular Atrophy (SMA) is characterized by
a loss of motoneurons in the ventral horn of the spinal cord,
progressive muscle weakness and muscular atrophy. SMA is
a monogenetic disease and all of the patients display deletions
or mutations of the Survival of Motoneuron 1 (Smn1) gene [1,2].
Humans possess one or more additional Smn2 gene copies, which
only differ in one translational silent mutation resulting in dif-
ferentially spliced mRNAs [3,4]. Only a small amount of fun-
ctional full-length SMN protein derive from the Smn2 gene,
thereby only partially rescuing the SMA-phenotype [5]. Moreover,
the number of Smn2-copies correlates positively with the amount
of SMN-protein and the severity of the disease, which can be
classified from severe (type I) to intermediate (type II) and mild
(type III) [6].
With regard to the pathology of SMA, the most prominent
feature of the disease is the degeneration of motoneurons.
However, there is still an ongoing debate whether this is a mo-
toneuron autonomous process or if there is a participation of other
tissues. Interestingly, a muscle specific rescue of SMN does not
lead to a significant benefit in survival and motor-function in a
mouse model of SMA [7]. A motoneuron autonomous role of
SMN is supported by experimental reduction of this protein in
single motoneurons of zebrafish, which leads to axonal outgrowth
and guidance defects [8]. However, some studies suggest a muscle
intrinsic pathology as well as a contribution of the target muscle to
motoneuron degeneration. In human SMA-fetus, a delay in
muscle-development could be observed prior to morphological
changes in motoneurons [9]. Moreover, a muscular SMN rescue
in SMA-Drosophila models shows benefits regarding stability of
neuromuscular junctions (NMJ) [10,11]. Importantly, co-culture
experiments demonstrate that myofibres derived from SMA-
patients are less capable of preventing apoptosis of rat embryo-
nic motoneurons than wild-type muscle-cells [12]. This study
additionally suggests a supporting role of target muscle for
motoneuron survival, most likely by secretion of neurotrophic
factors.
An important system of such neurotrophic factors is the
Fibroblast-Growth Factor (FGF) system. The FGF-system com-
prises four canonical FGF-receptor tyrosin kinases (FGFR) and
22 ligands. Besides their mitogenic effects, FGFs play important
roles in embryonic development of several tissues, regulation of
metabolic functions and control of homeostasis [13]. In muscle,
FGFs control differentiation during development, regeneration
in adult stages and carry out trophic functions [14,15,16]. With
regard to neuronal systems, some FGFs are known to improve
motoneuron survival either in a paracrine or autocrine fashion
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junctions and axonal outgrowth [19,20]. Widespread changes of
FGF-family members have been previously demonstrated for
pheochromocytoma cells (PC12) and as well as in vivo in forebrain
and brain stem of neonatal rats after exposure to organophos-
phates [21,22]. Thereby, the FGF-receptor tyrosin kinases act
mainly through ERK- and Akt-pathways which promote neuronal
survival as well as differentiation and neurite outgrowth (for review
see [23]). The latter is mediated by Rho-kinase (ROCK)-pathway-
signaling which in turn regulates actin-dynamics and stability of
neuromuscular junctions [24]. Recently, we could show that the
interaction of the SMN-protein with the neuronal actin-binding
protein Profilin2a is important for proper ROCK-pathway-
signaling and neurite outgrowth [25]. Importantly, ROCK-in-
hibition leads to prolonged survival in an intermediate SMA-
mouse-model [26]. However, neuronal differentiation is not only
controlled by extracellular FGF-ligands and transmembrane
FGFR acting as classical membrane associated signal-complexes.
FGFR-1 and its ligand FGF-2 can be imported into the nucleus
where they regulate transcription, thereby controlling neuronal
proliferation and differentiation [27]. Importantly, we could
previously show an interaction of nuclear FGF-2 with SMN con-
trolling the number of nuclear bodies (gems), which are known to
be reduced in SMA-patients [28,29,30]. Moreover, in a Drosophila
SMA-model, FGFR-orthologue heartless expressed in muscle has
been indentified to act synergistically with SMN on motor
endplate integrity [31].
Because of these evidences, we wanted to systematically elucidate
the involvement of the FGF-system in SMA-pathogenesis. In the
present study, we used quantitative reverse transcription PCR
(qRT-PCR) to compare transcript levels of all 22 FGF-ligands and 5
receptors of severely affected SMA-mice with control animals
during postnatal disease progression. Therefore, spinal cords and
muscles aswell ascorrespondingmuscular and motoneuron-likecell
line models of SMA were examined. In muscle, two of the main
expressedFGFRs weredownregulated. Inspinalcord,all of the four
canonical FGF-receptors were altered. Importantly, the highly
expressed FGF-receptor 1 was not only upregulated in pre-sym-
ptomatic state at postnatal day 1, but also in a SMA cell-culture
model ofthemotoneuron-likecellline NSC34.Consistentwiththat,
an analysis of FGFR-downstream targets revealed hyper-phosphor-
ylation of Akt and ERK. These results demonstrate widespread
alterations oftheFGF-systeminmuscleandspinalcord whichcould
lead to a disturbed muscle-motoneuron communication. Further,
these results show an involvement of the important ERK/Akt-
pathways in SMA which do not only act on a posttranslational level
– similar to the ROCK pathway – but also change gene-activity on
a transcriptional level.
Results
To study alterations of FGF-system in vivo we employed SMA-
mice modelling the genetic situation in SMA-patients. Homozy-
gous SMN-depleted animals with a human transgene for Smn2
(Smn
2/2; SMN2
tg/+) develop an SMA-type I like phenotype and
die at a mean age of 10 days. Animals with a heterozygous murine
depletion served as control animals (Smn
+/2; SMN2
tg/+) showing
no obvious symptoms with a normal life expectancy [32,33]. FGF-
expression in spinal cords of SMA- and control-animals was
examined at postnatal (P) days P1 (pre-symptomatic), P5 (sym-
ptomatic) and P8 (close to end stage), quadriceps femoris muscle at P1
and P5 via quantitative reverse transcription PCR (qRT-PCR)
(Fig. 1, 2). However, as tissues represent a mixture of different cell-
types, we employed cell line based models of SMA into our study
by knocking down SMN by SMN-specific siRNAs. Cells trans-
fected with scrambled control siRNA served as controls. The myo-
blastoma cell line C2C12 was included to model alterations of
muscle-cells in vitro [34], while NSC34 cells were used as an in vitro
model for motoneurons [35]. The knockdown efficiency for each
biological repetition was determined by western-blot analysis with
an anti-SMN-antibody for NSC34-cells (Fig. 3A, B) and C2C12-
cells (Fig. S1). To determine differences between the in-vivo FGF-
expression profile and the in vitro models, we compared transcript
abundances relative to internal housekeeping gene glyceraldehyde
3-phosphate dehydrogenase (GAPDH) in spinal cord or muscle of
control animals and respective cell lines (Fig. 1A, Fig. 2A). In a
next step, we quantified fold changes of all FGF receptors and
ligands in pooled samples. SMA-mice of each postnatal time point
or each biological replication in case of cells lines were compared
with their corresponding pooled control samples (data not shown).
Transcripts which displayed alterations in one of these screening
approaches were included in single sample studies by comparing
transcript levels of single SMA-animals and biological replications
of cell-line-models with respective controls (Fig. 1B, 2B).
Members of the FGF family are down-regulated in
SMA-mice muscle
To compare FGF expression profiles between C2C12 cells
and muscle tissue, we determined transcript abundances relative
to internal housekeeping GAPDH expression in pooled control
samples of P5-mouse tissues and control-siRNA transfected
C2C12 cells (Fig. 1A). In muscle 6 receptor-isoforms and 10 li-
gands were moderately to strongly expressed, while 4 of these
genes (FGFR-4, FGF-9, FGF-17 and FGF-18) were not detected
in C2C12-cells. On the opposite, FGF-12, FGF-15 and FGF-21
were much stronger or even exclusively expressed in C2C12-cells.
Regarding those FGFs expressed in both, muscle and cells, FGFR-
1b, FGFR-3c and FGF-2 displayed similar transcript abundances
in muscle tissue compared to C2C12 cells. In contrast, FGFR-1c,
2c and ligands 7 and 10 showed a higher expression level within
C2C12 cells whereas FGFR-5 and FGF-11 and 13 were more
abundant in muscle.
Next, we analyzed 10 genes which were positive for alterations
in the initial screening approaches of SMA-muscle against control
muscle in single sample studies (Fig. 1B). While differences of
pre-symptomatic P1 mice were not statistically significant (light
blue bars, Fig. 1B) symptomatic P5 mice (dark blue bars, Fig. 1B)
displayed significant downregulation of three receptors (FGFR-1c,
FGFR-2c, FGFR-4) and three ligands (FGF-11, FGF-16, FGF-18).
No significant differences of SMN knockdown and scrambled
siRNA treated C2C12 cells were observed (checked bars, Fig. 1A).
Interestingly, receptors 1c and 4, which were downregulated at
P5 in SMA muscle, displayed relative high expression levels
(Fig. 1A, B).
FGF-dysregulations in SMA-mice spinal cords
A comparison of transcript abundances between control NSC34
cells and control mouse spinal cord revealed similar mRNA
abundances for FGFR-1c, 1b and FGF-2 (Fig. 2A). In contrast,
spinal cord expressed 7 receptor-isoforms and 16 ligands whereas
only 3 receptor-isoforms and 11 ligands could be detected in
NSC34 cells. Spinal cord expressed 4 receptor-isoforms and 5
ligands exclusively. In general, the spinal cord displayed a broader
FGF and FGFR expression profile and higher overall expression
levels compared to NSC34 cells, which might reflect the high cell
type diversity within spinal cord tissue.
From 9 selected genes from the pooled cDNA screening,
alterations of four receptors (FGFR-1c, FGFR-3c, FGFR-4,
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PLoS ONE | www.plosone.org 2 February 2012 | Volume 7 | Issue 2 | e31202Figure 1. Expression and regulation of FGFs in muscle and C2C12-cells. (A) Transcript abundances relative to GAPDH in control muscle and
scrambled siRNA transfected C2C12-cells. FGF-mRNA levels were measured by qRT-PCR in pooled samples of P5 control mice tissues and pooled
samples of scrambled siRNA transfected cells relative to GAPDH as internal control. Transcript abundances were calculated from DCT-values. Unpaired
t-tests of technical repetitions of measurements in cell culture compared to tissue abundances were performed (n=2; n.s.=non significant, *p,0.05,
**p,0.01, ***p,0.001). Bars represent means with standard deviations (SD). (B) Fold-change of FGF transcript levels in SMA-mice muscle and C2C12
cells after SMN-knockdown. FGF transcript concentration was measured by qRT-PCR in SMA-mice muscle and SMN-siRNA treated C2C12-cells.
Transcript levels of SMA-mice and control animals were measured at P1 and P5. C2C12-cells were either transfected with SMN- or control scrambled-
siRNA in 4 independent experiments (n=4) with three replicates in each group. The knockdown for each experiment was monitored by western-blot
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verified in individual SMA-animals at least at one postnatal time
point (Fig. 2B). FGFR-4 and -5 as well as ligands FGF-9 and -11
displayed a similar pattern with regard to their developmental
regulation. An upregulation at P1, which was significant for FGF
receptors 4 and 5 and occured as a trend for FGF-9 and -11, was
followed by a significant down-regulation at P8. In contrast, up-
regulation of FGFR-3c continuously increased during disease
progression, whereby FGF-2 demonstrated a small, but significant
change at P5. Importantly, upregulated FGFR-1c at pre-symptom-
atic stage P1 was also observed in NSC34 cells under SMN-
knockdown conditions. Comparing in vivo and in vitro situations,
these regulative effects were much stronger in NSC34-cells than in
P1 spinal cords (Fig. 1B, light blue bars and checked bars).
SMN-knockdown in NSC34 cells led to
hyper-phosphorylation of FGFR-1 downstream
targets Akt and ERK
Since we have found significant up-regulation of FGFR-1 both
in SMA spinal cord and the SMA in vitro NSC34-model, we next
addressed putative activation of FGFR-1 downstream targets.
Therefore, we analyzed phosphorylation changes of Akt and ERK
after SMN knockdown in NSC34 cells (Fig. 3A).
SMN-knockdown in NSC34 cells demonstrated its efficient
down-regulation similar to levels observed in primary fibroblasts
derived from type-1 SMA patients ([36], Fig. 3B). Consistent
with the up-regulation of FGFR-1c transcript levels (Fig. 2B), we
found Akt as well as ERK to be significantly hyper-phosphorylated
(Fig. 3C, D), indicating over-activation of both pathways.
In order to analyze the functional link between enhanced
FGFR-1 expression and ERK-hyper-phosphorylation we applied
the small compound PD173074 which binds the tyrosin kinase
domain of FGFR-1 and efficiently inhibits its activity [37,38].
As expected, addition of FGF-2 to the culture medium strongly
increased pERK levels in both control and SMN-knockdown cells
(Fig. 3E, F). Interestingly, the upregulation of pERK under SMN
knockdown was maintained, supporting involvement of FGFR-1
upregulation in SMN-dependent ERK-hyperphosphorylation.
Most importantly, this ERK-hyperphosphorylation disappeared
under FGFR-1 inhibition by PD173074, both in FGF-treated and
untreated cells which shows that FGFR-1 tyrosin kinase activity
is responsible for accumulation of pERK. Efficient FGFR-1
inhibition was shown by hypo-phosphorylation of cRAF (Fig. 3E)
which acts downstream of FGFR-1 (Fig. 4). These results show for
the first time a SMN-knockdown induced upregulation of FGFR-1
expression which leads to an ERK-hyper-phosphorylation. More-
over, also pAkt accumulates which supports FGFR-1 upregulation
being responsible for the observed effects. Furthermore, the in-
volvement of these pathways in SMN-dependent processes such as
neurite outgrowth and apoptosis points to a possible role of these
central signal integrators in SMA-pathogenesis.
Discussion
In this study, we could show multiple dysregulations within the
FGF-system of a mouse model of SMA both in muscle and spinal
cords. Importantly, the upregulation of FGFR-1c in spinal cord at
presymtomatic state P1 could also be observed in an NSC34-cell
culture model of SMA. Consistently, we could show a hyper-
phosphorylation of FGFR-1 downstream targets ERK and Akt.
The FGF-system comprises 22 ligands and 4 high affinity receptor
tyrosin kinases [13]. A fifth receptor FGFR-5 has no intracellular
kinase domain and might carry out regulatory functions by se-
questering FGF-ligands from their high affinity receptor targets
[39]. Importantly, our group could previously show an interaction
of an intracellular FGF-2 isoform, FGF-2
23 with the SMN-protein
regulating stability of nuclear gems [28,29,30]. Nuclear FGF-2
is known to act on neurite outgrowth which is impaired in several
SMA in vitro models possibly linking nuclear FGF to SMA pa-
thology [40]. Regarding neuronal systems in general, the FGF-
system is known to play important roles in neuronal survival,
axonal guidance, target recognition and maturation of neuromus-
cular junctions (for review see [41]); processes which are affected
by SMN. In muscle, FGFs carry out muscle intrinsic functions
such as muscle cell survival as well as muscle derived support of
motoneuron survival [42,43,44].
Our expression analysis of spinal cord and muscle tissues in
comparison with corresponding motoneuron-like NSC34- and
myoblastoma C2C12-cells, revealed considerable differences
between in vivo and in vitro expression of FGF-ligands and re-
ceptors. As tissues represent a mixture of different cell types, it
is most likely to detect FGF-expression of cell-types other than
motoneurons or muscle cells. Thus, it is not surprising to find more
FGFs to be expressed in tissues when compared with correspond-
ing cell-lines. Only very few ligands are exclusively expressed in
cell lines which might be attributable to the in vitro situation of
cell culture or to their expression in blastoma cells. Because of
normalization to GAPDH – which itself could be differentially
expressed considering tissues and cell lines – this kind of analysis is
intrinsically limited. However, since the observed differences for
the FGF-system between expression in tissues and cell lines are
relatively large, the data provide useful estimations for comparison
of expression levels. Regarding expression in spinal cord, our
results are in agreement with previous findings of our group,
except for low expressed FGF-5 and 21 which were close to
detection limit [45]. These observed differences might be due
to genetic background effects of FVN or C57BL6 mice strain
analyzed. The weaker elevation of FGFR-1c in P1 spinal cords of
SMA-animals compared to NSC34-cells under SMN-knockdown
might be a masking effect of non-regulated cell-types in tissue. As
the upregulated FGFR-1 is the only FGF-receptor tyrosin kinase
expressed in NSC34-cells, redundancy by other FGF-receptors
can be excluded. Therefore NSC34-cells represent an excellent in
vitro model for FGFR-1 functions.
In quadriceps femoris muscles, we could show a down-regulation of
several receptors and ligands at P5. At this stage, it is unknown at
which extent this particular muscle is affected by the disease
complicating the integration of these events into the natural history
of disease. However, our findings of downregulated receptors 1
and 4 might point to a role of FGFs in a muscle intrinsic pathology
of SMA. An inhibition of FGFR-4 signaling in chicken embryos
leads to impaired muscle cell progenitor differentiation and limb
bud myogenesis [15]. FGFR-4 null mice, however, show no de-
velopmental phenotype [46], but more importantly an impairment
analysis (Fig. S1). The fold-changes were calculated against each corresponding control group. Fold-changes of SMA-mice spinal cords were
calculated against transcript levels of control mice of the same age. Results of SMN siRNA treated cells were compared to scrambled RNA transfected
cells of the same experiment. SMA-mice transcript levels were tested against control animals by a Mann-Whitney test (n$5, * p,0.05, ** p,0.01).
mRNA-levels of SMN siRNA transfected cells were compared to scrambled siRNA transfected cells by a repeated measurements two way ANOVA
(n=4). Bars for fold changes represent means with standard error of mean (SEM).
doi:10.1371/journal.pone.0031202.g001
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PLoS ONE | www.plosone.org 4 February 2012 | Volume 7 | Issue 2 | e31202Figure 2. Expression and regulation of FGFs in spinal cord and NSC34-cells. (A) Transcript abundances relative to GAPDH in control mice
spinal cords and scrambled siRNA transfected NSC34-cells. FGF mRNA levels were measured by qRT-PCR in pooled samples of P5 control mice tissues
and scrambled siRNA transfected cells relative to GAPDH as internal control. Transcript abundances were calculated from DCT-values. Unpaired t-tests
of technical repetitions of measurements in cell-culture compared to tissue abundances were performed (n=2; n.s.=non significant, *p,0.05,
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FGFR-1 can only be found in differentiated postmitotic myoblasts
of chicken embryos indicating a role in adult muscle [47]. Con-
sistently, FGFR-1 mRNA is upregulated in less affected muscles
during disuse-mediated skeletal muscle atrophy. In vivo overex-
pression of FGFR-1 protects from myofibre size decrease [14].
Interestingly, SMN-knockdown in C2C12 cells leads to reduced
proliferation as well as defects in myoblast-fusion [48]. Moreover,
SMA-fetus predicted to develop SMA-type I, show a delay
in growth and maturation of myotubes prior to morphological
changes occurring in spinal cords [9]. Thus, FGFR-1 and 4
downregulations in SMA-mice might fulfill negative modulating
roles in myotube differentiation and muscular atrophy. However,
although there is still an ongoing debate whether changes in
muscle occur as a result of changes in motoneurons or de-
nervation, there is growing evidence of a muscle intrinsic
pathology in SMA. On a cellular level, the SMN-complex lo-
calizes to sarcomeric Z-discs both in Drosophila and mice. A role of
the SMN-complex in Z-disc integrity, signaling to the nucleus
and/or mRNP transport was suggested [49,50]. Moreover, recent
**p,0.01, ***p,0.001). Bars represent means with standard deviations (SD). (B) Fold-change of FGF transcript levels in SMA-mice spinal cords and
NSC34 cells after SMN-knockdown. FGF transcript concentration was measured by qRT-PCR in SMA-mice spinal cords and SMN-siRNA treated NSC34-
cells. Transcript levels of SMA-mice and control animals were measured at P1, P5 and P8. NSC34-cells were either transfected with SMN- or control
scrambled-siRNA in four independent experiments (n=4) with three replicates in each group. The knockdown for each experiment was monitored by
western-blot analysis (Fig. 3). The fold-changes were calculated in comparison to each corresponding control group. Fold-changes of SMA-mice
spinal cords were calculated compared to transcript levels of control mice of the same age. Results of SMN siRNA treated cells were calculated
compared to scrambled RNA transfected cells of the same experiment. SMA-mice transcript levels were tested against control animals by a Mann-
Whitney test (n$5, *p,0.05, **p,0.01). mRNA-levels of SMN siRNA transfected cells were tested against scrambled siRNA transfected cells by
repeated measurements two way ANOVA (n=4, **p=0.0046). Bars for fold-changes represent means with standard error of mean (SEM).
doi:10.1371/journal.pone.0031202.g002
Figure 3. Western blot analysis of NSC34-cells after SMN-knockdown. (A) Phosphorylation of FGF-downstream targets Akt and ERK was
analyzed in siRNA treated (si) and scrambled siRNA (scr) transfected cells. Phospho-antibodies against Akt (pAkt, S473), and ERK1/2 (pERK, T202,T204)
were used to quantify changes in phosphorylation levels compared to non-phosphorylated Akt, ERK. Four independent experiments with three
replications were performed. (B) Densitometrical measurements of SMN-bands normalized by a-tubulin showed an efficient knockdown of 2065% in
comparison to control-siRNA-transfected cells. (C) pAkt normalized to non-phosphorylated Akt was upregulated by a factor of 2.860.7. (D) pERK
normalized to non-phospho-ERK was upregulated by a factor of 2.160.3. (E) The functional link between FGFR-1 signaling and ERK-
hyperphosphorylation was analyzed by application of the specific FGFR-1 inhibitor PD173074 (50 mM). Additionally, FGF-2 was added to the medium
in a final concentration of 50 ng/ml. (F) Densitometrical measurements of pERK normalized to non-phospho ERK revealed an upregulation of
10.663.1 fold in scrambled siRNA transfected cells under FGF-2 incubation compared to scrambled siRNA transfected control conditions. When
transfected with SMN siRNA, the pERK level rises up to 23.760.6 fold change. These differences disappeared after PD173074 incubation. Bars and
values represent means with standard error of mean (SEM). Significance was tested via repeated measurements two-way ANOVA (B, C, D, n=4,
***p,0.0001, **p,0.01, *p,0.05) and paired ratio t-test (F, n=6 for control conditions and n=3 for remaining conditions, **p,0.01, *p,0.05).
doi:10.1371/journal.pone.0031202.g003
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affected muscles point to a muscle intrinsic pathology of SMA
involving cellular survival pathways [51]. Interestingly, a muscular
overexpression of insulin like growth factor 1 (IGF-1), which is
known to lead to muscle-hypertrophy, also increases muscle mass
in SMA-mice and enhanced survival rates [52,53].
Several publications in recent years suggested an impaired
muscle-dependent maturation and maintenance of the neuromus-
cular junctions (NMJ) during postnatal development in SMA.
Muscle specific reduction of SMN resulted in lower numbers of
synaptic boutons at the NMJ [10] and a muscular SMN-rescue
improved survival of SMA Drosophila models [11]. In vitro
experiments show that SMA-patient derived muscle cells are less
capable of preventing apoptosis of rat primary motoneurons than
controls [12]. These results indicate an impaired motoneuron-
muscle communication caused by reduced SMN-levels in muscle
cells leading to cell death in motoneurons. Remarkably, SMN-
knockdown inDrosophilaleadstoreduced mRNAlevelsoftheFGFR
orthologue heartless (htl) in larval brains. Moreover, a mesoderm-
specific (muscle) SMN-knockdown results in a reduction of
postsynaptic accumulation of htl and a reduced number of synaptic
boutons which could be rescued by mesoderm-specific overexpres-
sion of htl [31]. Importantly, the SMN-dependent reduction of htl in
Drosophila is consistent with our findings of down-regulated FGFRs
in SMA-mice muscle. However, as Drosophila only expresses two
FGFRs and three ligand orthologues, these results are difficult to
compare to mice. A possible role of postsynaptically expressed
FGFRs in NMJ integrity of mice has not yet been investigated.
In spinal cord, we could show alterations of 4 receptors and 3
ligands. Importantly, the upregulation of FGFR-1 in spinal cord
could be observed at the pre-symptomatic stage P1. NSC34 cells
under SMN-knockdown resemble this regulation and show a
sustained ERK1/2-activation. Expression of FGFR-1, which
selectively signals through MAPK/ERK in vitro, is crucial for fiber
outgrowth and guidance. FGFR-1 knockout motoneurons trans-
planted into neural tube of chicken embryos show severe guidance
defects [54]. Importantly, motoneurons transfected with constitu-
tively active MEK, an upstream activator of ERK, also showed
defects in axonal guidance. Thus, proper guidance needs a fine
regulation of FGFR-1 dependent signaling through the MEK/
ERK-pathway [54]. Therefore, our observations of upregulated
FGFR-1 in SMA-mice spinal cords might point towards SMN-
dependent guidance and outgrowth defects. Interestingly, a
zebrafish model of SMA with a SMN-reduction in single moto-
neurons leads to axonal outgrowth and guidance defects [8].
Moreover, we could recently show SMN-dependent changes
in actin-dynamics and signaling pathways controlling neurite
outgrowth [25,55].
FGFR-1 is known to act via two pathways on neurite outgrowth,
MEK/ERK and PI3K/Akt. Consistent with our findings of
Figure 4. Crosstalk of neurotrophic factor signaling and ROCK pathway leading to neurite outgrowth – involvement of SMN
protein. FGF-signaling promotes neurite outgrowth by small GTPase-dependent-, ERK- and Akt-pathways. Activation of the small GTPases Rac and
Cdc42 and inhibition of the negative effector RhoA promotes outgrowth by posttranslational mechanisms. The ERK and Akt pathways, however,
change transcriptional profiles towards an outgrowth promoting state. Both pathways functionally interact with RhoA-downstream-target Rho-kinase
(ROCK) as a central node [58,65]. ROCK thereby is important for integration and processing signals of the two major pathways involved in neurite
outgrowth. Interestingly, recent findings of our group suggest a role of SMN-Profilin2a interaction in ROCK-pathway dependent outgrowth. SMN-
reduction thereby leads to changes in phosphorylation-dependent regulation of ROCK-downstream targets indicated by red arrows [25]. Moreover,
SMA-patient derived SMN-S230L-mutation does not interact with Prof2a and acts dominant negative on neurite outgrowth when overexpressed in
vitro [25]. In this study, FGFR-1 was found to be upregulated under SMN-knockdown and consistently Akt and ERK showed hyper-phosphorylations.
Thereby a sequestration of ROCK via Prof2a binding might enhance ERK-hyper-phosphorylation in a FGFR dependent manner.
doi:10.1371/journal.pone.0031202.g004
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phosphosphorylated in NSC34 cells under SMN-knockdown. In
PC12 cells, FGFR activation leads to a sustained ERK-activation
and subsequently to neurite outgrowth [56]. PI3K/Akt and
MEK/ERK pathways are both necessary for neurotrophic factor
mediated axonal outgrowth [57]. Neurotrophic signaling, medi-
ated by PI3K/Akt and MEK/ERK-pathways, finally activates
transcription factors promoting neuronal differentiation as well as
they directly signal to small GTPases Rac, Cdc42 and RhoA
upstream of rho kinase (ROCK) (for review see [23]). In an
intermediate SMA-mouse model, an inhibition of ROCK leads to
improved NMJ-maturation and increased lifespan [26]. Moreover,
our group could demonstrate changes in F-/G-actin ratios under
SMN knockdown conditions in PC12 cells and motoneurons
of SMA mice [25,55]. Mechanistically, we could identify
Profilin2a (Prof2a) as a binding partner of the SMN-protein.
Since Prof2a also binds to ROCK, it links SMN-reduction with
dysregulation of actin-dynamics (Fig. 4). Moreover, we could show
widespread dysregulations within the signaling network regulating
actin-dynamics leading to neurite outgrowth inhibition. Thereby,
SMN reduction causes a release of Prof2a from SMN-Prof2a
complex which in turn binds ROCK inducing a sequestration of
ROCK from other downstream targets [25]. Interestingly, the
ROCK pathway is also linked to the MEK/ERK-pathway (Fig. 4).
In PC12 cells, an inhibition of ROCK leads to enhanced FGFR
induced ERK-phosphorylation, which does not occur without any
FGFR stimulus [58]. Similarly, a stimulus by ciliary neurotrophic
factor (CNTF) and a simultaneous inhibition of ROCK results in
hyper-phosphorylated ERK1/2 in retinal ganglion cells and in a
Akt hyper-phosphorylation [59]. Thus, a sequestration of ROCK
by enhanced Prof2a binding under SMN reduction and a
simultaneous FGFR-1 upregulation explain the sustained ERK
and Akt-phosphorylation observed in this study. While a transient
ERK activation promotes neuronal survival, a sustained ERK
activation might cause cell death suggesting a role of ERK in
neurodegenerative processes (for review see [60]). Interestingly,
our findings of upregulated FGFR-3c and FGF-2 also match a cell
death promoting pattern. Both, FGFR-3 and FGF-2 knockout
mice show less apoptosis of spinal ganglia sensory neurons after
sciatic nerve axotomy implicating a negative modulating role of
the FGFR-3/FGF-2 interaction on survival in neurodegenerative
processes [61]. In accordance with that, apoptosis in retina cell
development is induced by FGF-2. Moreover, FGF-9, which we
could show to be downregulated in SMA-mice spinal cords, is
known to be expressed in human and rat motoneurons [62] and in
vitro experiments reveal a survival promoting role of FGF-9 on
motoneurons [17].
Taken together, we could show widespread alterations within
the FGF-system of SMA-mice muscle and spinal cords. Dysreg-
ulations in muscle might be associated with muscle-intrinsic
functions such as myotube differentiation but also with NMJ-
maintenance defects. Dysegulations in spinal cord might contrib-
ute to cell-death of motoneurons. Importantly, the upregulation of
FGFR-1 could be modelled in NSC34-cells and most likely leads
to hyperphosphorylation of FGFR downstream targets Akt and
ERK. As both molecules are linked to ROCK-signaling and
neurite outgrowth as well as they control cell death, they represent
valuable targets of future investigations in the field of SMA.
Materials and Methods
Animals
The mouse mutant strain FVB.Cg-Tg(SMN2)2Hung
SMN1
tm1Hung/J [32] was purchased from the Jackson Laboratory
(stock number 005058). To obtain 50% SMA-mice (Smn
2/2;
SMN2
tg/+) and 50% control littermates (Smn
+/2;SMN2
tg/+), mice
were bred and genotyped as described previously [25]. After
decapitation, spinal cords and left and right quadriceps femoris
muscles were dissected and immediately frozen in liquid nitrogen.
All experimental protocols followed German law on animal care
(study approval not necessary for tissue preparation as covered by
1 4, Abs. 3 TierSchG).
Cell Culture and transfection
Cells were incubated at 37uC in 5% humidified atmosphere.
NSC34 cells were grown in Dulbecco’s modified Eagle medium
(DMEM) with low glucose content, 5% (v/v) fetal calf serum
(FCS), 200 mM L-glutamine, 100 U/ml penicillin and 0.1 mg/ml
streptomycin. For siRNA-knockdown, medium was changed to
differentiation medium containing 1% (v/v) FCS instead of 5%.
Immediately, siRNA-transfections were performed according to
the manufacturer’s recommendations using MetafectenePro
(Biontex). C2C12-cells were maintained in high glucose DMEM
containing 10% (v/v) FCS, 100 U/ml penicillin and 0.1 mg/ml
streptomycin. For siRNA-transfections, medium was changed to
differentiation medium containing 5% (v/v) horse serum instead of
10% FCS. Both NSC34 and C2C12-cells were harvested 7262h
after siRNA-transfection. Three different SMN-siRNAs (synthe-
sized by eurofins) were used for validation of results: siRNA2
(AUGCCUUUAGAAUAAAUAAA), siRNA3 (AAGAAGGAAA-
GUGCUCACAUA), siRNA4 (CAGAAGUAAAGCACACAG-
CAA) against murine SMN and scrambled control siRNA
(GCGCAAAUAAACCGAAAGACA). No obvious differences in
SMN-knockdown efficiency between different SMN siRNAs could
be observed. FGFR-1 inhibitor PD173074 (Calbiochem, CAS
219580-11-7) was added 2 h prior to cell lysis in a final con-
centration of 50 mM. FGF-2 (PeproTech, Cat. 100-18-B) was
added 10 min prior to lysis in a final concentration of 50 ng/ml.
Cell-culture experiments depicted in figures 1, 2 and 3 A, B, C, D
were repeated in four independent biological replications whereas
three replications were carried out for experiments depicted in
figures 3 E, F.
RNA-Isolation and reverse transcription
RNA was isolated using the RNeasy Mini Kit (Qiagen)
according to the manufacturer’s recommendations. 2.5 mg of total
RNA was reversely transcribed at 42uC in a total buffer-volume
of 40 ml containing 3 mg random hexamer primers (Invitrogen),
200 U M-MLV-transcriptase (Invitrogen), 40 U RNase-Inhibitor
(Agilent), 0.02 mmol dNTPs (Invitrogen) and 0.4 mmol DTT
(Invitrogen). In a first step, RNA and random hexamer primers
alone were incubated at 70uC followed by a rapid cooling step.
Subsequently, the other components were added and incubated
at 42uC for 1.5 h. Transcriptase was denatured by 15 min in-
cubation at 70uC. For real-time PCR-applications, cDNA was
diluted 1:200.
Realtime PCR
5 mld i l u t e dc D N A ,7ml of Power SYBRgreen (Applied Biosys-
tems) and 2 ml primer dilution (1.75 mM each) were mixed in a 96-
well MicroAmp reaction plate (Applied Biosystems). Realtime-PCR
was performed using the StepOnePlus-thermocycler (Applied
Biosystems). After aninitial10 min step of95uC,PCRwasperformed
for 40 cycles (15 s 95uCa n d1m i n6 0 uC). Primer sequences have
been reported previously [45]. PCR-product specificity was verified
by melt-curve analysis and compared to previous reported values
[45]. Stability of three housekeeping genes was examined for each
condition (Hprt1, Ppia, GAPDH). GAPDH-primers [63] were
The FGF-System in SMA
PLoS ONE | www.plosone.org 8 February 2012 | Volume 7 | Issue 2 | e31202chosen for quantification of mRNA abundances in pooled samples of
tissues and cell lines (Fig. 1A, Fig. 2A). Further, they were applied to
quantify fold changes in tissues (Fig. 1B, Fig. 2B). Peptidylprolyl
isomerase A (Ppia)-primers were chosen to quantify fold changes of
cell lines (Fig. 1B, Fig. 2B, checked bars), because GAPDH displayed
small but reproducible changes among the two conditions, whereas
Hprt1 and Ppia were not regulated. CT-values were calculated with
StepOne-software version 2.1 using a constant cycle threshold of 0.2.
Quantification was performed using 2
2DDC
T-method [64] giving fold
changes in mRNA-levels relative to the arithmetic mean of the
corresponding control group. Transcript abundances (Fig. 1A,
Fig. 2B) relative to GAPDH were calculated by 2
2DC
T for control
conditions (P5 in case of animal tissues). Although a comparative
interpretation of relative transcript levels between different transcripts
is limited, it provides rough qualitative information about expression
levels.
Western blot
Cells were lysed with RIPA-buffer (137 mM NaCl, 20 mM
Tris-HCl pH 7, 525 mM b-glycerophosphate, 2 mM EDTA,
1 mM sodium-orthovanadate, 1% (w/v) sodium-desoxycholate,
1% (v/v) Triton-X-100, protease inhibitor cocktail (Roche) and
equal amounts of total protein (80–120 mg) in Laemmli-buffer
(80 mM Tris-HCl pH 6.8, 2% SDS (w/v), 5% (v/v) 2-mercap-
toethanol and 0.01% (v/v) bromphenol blue) were loaded on 10%
polyacrylamide/SDS-gels. After electrophoretic separation, pro-
teins were blotted on nitrocellulose membranes (GE Healthcare)
and detected by horseradish-peroxidase linked secondary antibod-
ies. Densitometric quantification of bands was performed with
ImageJ software (version 1.43u). The following antibodies were
used: mouse anti-SMN monoclonal (BD Biosciences), mouse anti
tubulin (Santa Cruz Biotechnology, Inc.), rabbit anti pERK1/2
(T202, T204, Cell Signaling), mouse anti ERK1/2 (Cell Sig-
naling), rabbit anti pAkt (S473, Cell Signaling), rabbit anti Akt
(Cell Signaling), rabbit anti pcRAF (S338, Cell Signaling) and
rabbit anti cRAF (Cell Signaling).
Statistical analysis
Statistical analysis was done using GraphPad Prism 4 software.
Mann-Whitney tests of fold changes of SMA-animals compared to
control animals were performed for each postnatal time point
individually. Realtime PCR of NSC34- and C2C12-cells was done
in 4 independent biological replications with 3 cell culture
repetitions for each group (SMN-siRNA-transfected and scram-
bled siRNA-transfected). Statistical significance was tested by
repeated measures two-way ANOVA. Densitometric values of
phosphoprotein-bands were normalized to those of the corre-
sponding non-phosphorylated protein-bands. Four independent
experiments with 3 repetitions of each group were quantified and
tested by repeated measures two-way ANOVA for experiments
depicted in figures 1, 2 and 3 A–D. At least three independent
experiments were quantified and tested by paired ratio t-tests for
experiments depicted in Fig. 3 E, F.
Supporting Information
Figure S1 SMN-knockdown in C2C12-cells. (A) Anti SMN
western-blots of SMN siRNA transfected C2C12 cells in com-
parison to scrambled siRNA-transfection. Four independent ex-
periments with three replications were performed. (B) Densitome-
trical measurements of SMN-bands normalized to a-tubulin
showed a knockdown of 3762.9% in comparison to control-
siRNA-transfected cells. Bars and values represent means with
standard errors of mean (SEM). Significance was tested by re-
peated measurements two-way ANOVA (n=4, ***p,0.001).
(TIF)
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